Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol added to standard care for neonatal hypoxic-ischemic encephalopathy
NL-OMON59831Phase 3Completed
- Sponsor
- University Hospital Tübingen
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypoxic-ischemic encephalopathy (HIE) comparing Allopurinol plus standard care with Placebo plus standard care (2 arms). Started May 2018; status: completed.
02
Drugs
allopurinol
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NL-OMON59831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59831.